Skip to main content
. Author manuscript; available in PMC: 2022 Nov 30.
Published in final edited form as: Nat Cancer. 2022 May 30;3(7):808–820. doi: 10.1038/s43018-022-00383-0

Extended Data Fig. 6. Increased efficacy of CAR T cells engineered to inactivate PARP11.

Extended Data Fig. 6

A. qPCR analysis of PARP11 mRNA in shCON-CD19-BBz or shPARP11-CD19-BBz CAR T cells. Data are shown as mean ± SEM (n = 5 independently treated cell cultures.). Two-tailed unpaired t-test was performed for the comparisons between groups. ****P < 0.0001.

B. Flow cytometry analysis of CAR expression in human T cells 3 days after shCON-CD19-BBz or shPARP11-CD19-BBz transduction.

C. In vitro proliferation of shCON-CD19-BBz and shPARP11-CD19-BBz CAR T cells following stimulation with anti-CD3/CD28 microbeads. Data are shown as mean ± SEM (n = 3 independently treated cell cultures). Statistical analysis was performed using two-way ANOVA with Tukey`s multiple comparisons test.

D. qPCR analysis of PARP11 mRNA in human WT or PARP11 knockout (PARP11 sgRNA) Meso-BBz CAR T cells. Data are shown as mean ± SEM (n = 5 independently treated cell cultures). Two-tailed unpaired t-test was performed for the comparisons between groups. ****P < 0.0001.

E. Flow cytometry analysis of IFNAR1 cell surface levels on human WT or PARP11 knockout (PARP11 sgRNA) Meso-BBz CAR T cells. Data are shown as mean ± SEM (n = 5 independently treated cell cultures). Two-tailed unpaired t-test was performed for the comparisons between groups. *P = 0.0128.

F. Analysis of killing of EM-Meso-GFP-Luc cells cocultured with human WT or PARP11 knockout (PARP11 sgRNA) Meso-BBz CAR T cells. Data are shown as mean ± SEM (n = 5 independently treated cell cultures). Two-tailed unpaired t-test was performed for the comparisons between groups. ***P = 0.0006.